核医学市场份额，规模，趋势，行业分析报告，按类型（诊断，治疗，其他）;通过模态（β发射器，宠物，SPECT，α-发射器，近距离放射治疗，其他）;通过申请;通过最终使用;按地区;分部预测，2021 - 2028

报告摘要

The global nuclear medicine market size was valued at USD 6.19 billion in 2020 and is anticipated to grow at a CAGR of 9.0% during the forecast period. Nuclear medicine involves the use of radiotracers for the diagnosis and treatment of cancer, neurological, cardiovascular, and other disorders at early stages. The radiotracers traverse through the body and emit gamma rays, which are detected by the camera, and processed by a computer to create a scan. Nuclear medicine is increasingly being used for the early detection of cancer. It also assists in planning treatment, analyzing the response, and reoccurrence of cancer.

了解有关此报告的更多信息：请求样本页面

Nuclear medicine is capable of offering information about the tumor, metastasis, and remission. The imaging technology identifies the location of cancer cells and the possibility of treatment options. It is also used for applications such as renal scan, bone scan, lung scan, thyroid scan, and myocardial perfusion scan, among others.

The demand for therapeutic nuclear medicine is expected to increase during the forecast period. Radioactive iodine therapy is increasingly being used for the treatment of hyperthyroidism and甲状腺癌，而使用放射性抗体的使用能够治疗淋巴瘤。放射性磷也用于治疗某些血液疾病。

The use of nuclear medicine offers enhanced treatment options for diseases such as cancer. It offers extremely high accuracy and precision in the detection of severe and complicated medical conditions, resulting in early-stage treatment. Nuclear medicine is capable of a detailed and exhaustive analysis of body functions and patient anatomy for effective diagnosis and treatment courses to be followed.

新产品发布和收购主要players in the market have increased the adoption of nuclear medicine across the globe. In January 2018, Norgine B.V. introduced LYMPHOSEEK for distribution in Finland and Sweden. LYMPHOSEEK is a radiopharmaceutical aimed at providing effective diagnosis through nuclear medicine.

开发的是用于Sentinel淋巴结活组织检查，用于诊断乳腺癌和黑色素瘤等。2018年12月，Novartis获得了内联曲线，Inc。，为癌症治疗的Radioligand和Car-T疗法的发展。此次收购旨在扩大该公司在核医学和放射性地疗法的诊断和治疗癌症的疗法。

全球放射性药物市场被中国，日本和印度等国家的增长所促进的，需要提供有效的医疗保健服务，增加的老年人口，慢性疾病的不断增长的病例以及提供增强的患者体验的需要。betway体育亚洲版入口必威开户注册全球参与者正在扩展发展中经济体，以挖掘市场潜力，进一步提高市场增长。

Growing healthcare expenditure, changing lifestyles, and the introduction of supportive healthcare regulations would support the growth of the market. Technological advancements and significant investments in research and development further stimulate market growth for radiopharmaceuticals.

Nuclear Medicine Market Report Scope

该市场主要根据类型，模当，申请，最终使用和区域进行分段。

By Type	By Modality	By Application	By End-Use	By Region
诊断 治疗 Others	β发射器 宠物 Spect. Alpha-emitters Brachytherapy Others	甲状腺 Cardiology 骨转移 肿瘤学 Neurology Gastroenterology Immunology Others	医院 诊所和诊断中心 研究institutes Others	北美（美国，加拿大） Europe (Germany, UK, France, Italy, Spain, RoE) Asia Pacific (China, India, Japan, South Korea, RoAPAC) Latin America (Brazil, Mexico, Colombia, RoLATAM) Middle East & Africa (Saudi Arabia, South Africa, Israel, UAE, RoMEA)

了解有关此报告的更多信息：请求样本页面

类型Outlook.

On the basis of type, the market is segmented into diagnostic, therapeutic, and others. The diagnostic segment dominated the global radiopharmaceuticals market in 2019. Nuclear medicine uses radiotracers, which accumulate in tumors and provide accurate scans. Technetium-99m is used for diagnosis of heart diseases through PET. Nuclear medicine is also used for detection of thyroid through the use of radioactive iodine thyroid scan. Hepatobiliary iminodiacetic acid (HIDA) scans combined with technetium-99m are used for diagnosis of gallbladder problems.

Modality Outlook

On the basis of type, the market for nuclear medicine is segmented into diagnostic, therapeutic, and others. The diagnostic segment dominated the global radiopharmaceuticals market in 2019. Nuclear medicine uses radiotracers, which accumulate in tumors and provide accurate scans. Technetium-99m is used for the diagnosis of heart diseases through PET. Nuclear medicine is also used for the detection of the thyroid through the use of radioactive iodine thyroid scans. Hepatobiliary iminodiacetic acid (HIDA) scans combined with technetium-99m are used for the diagnosis of gallbladder problems.

Application Outlook

在申请的基础上，市场被分段为甲状腺，心脏病学，骨转移，肿瘤学，神经病学，胃肠学，免疫学等。核医学用于检测和诊断冠状动脉疾病，分析心脏移植后接受，并检查治疗方案。它还用于调查心脏病发作后造成的损害，检查化疗对心脏功能的影响，分析血运重建程序的结果。

最终使用前景

在申请的基础上，该市场被分段为甲状腺，心脏病学，骨转移，肿瘤学，神经病学，胃肠学，免疫学等。核医学用于检测和诊断冠状动脉疾病，分析心脏移植后接受，并检查治疗方案。它还用于调查心脏病发作后造成的损害，检查化疗对心功能的影响，分析血运重建程序的结果。

Geographic Overview

北美占2020年全球核医药市场。增加老年人口，日益增长的研发活动，有关使用医疗同位素的支持条例，以及技术进步是归因于该区域细分的增长的因素。

There have been increasing incidences of chronic diseases registered in the region, driving the growth of this region. Rising health concerns established healthcare infrastructure, and growing awareness regarding preventive healthcare and early diagnosis of diseases has increased the demand for nuclear medicine in the region.

Competitive Landscape

The leading players in the nuclear medicine market include Bracco Imaging S.P.A., Lantheus Medical Imaging, Inc., NTP Radioisotopes Soc, LTD, Eckert & Ziegler Group, Jubilant Pharma LLC, Australian Nuclear Science & Technology Organization, Cardinal Health, Isotopia Molecular Imaging Limited, Bayer AG, The Institute for Radioelements, Curium SAS, Advanced Accelerator Applications, Nordion, Inc., Mallinckrodt, and GE Healthcare.